by TractManager | Aug 22, 2019 | Health Technology Assessment
Health Problem: Uterine fibroids (UFs) (also called leiomyomata or myomas) are benign tumors of the myometrium, the smooth muscle layer of the uterus. Approximately 25% of fibroids are symptomatic. Fibroids are the most common indication for hysterectomy in many...
by TractManager | Aug 21, 2019 | Health Technology Assessment
Health Problem: Headache is a common disorder affecting more than 45 million individuals in the United States. There are several types of headache, with symptoms that vary with the underlying pathophysiology. Headaches can be primary, such as migraine, cluster, and...
by TractManager | Aug 19, 2019 | Emerging Technology Report
Balversa is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations and has progressed during or...
by TractManager | Aug 19, 2019 | Emerging Technology Report
Rozlytrek (entrectinib) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) rearrangements. Rozlytrek is indicated for the treatment of adult and...
by TractManager | Aug 19, 2019 | Emerging Technology Report
Balversa is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations and has progressed during or...
Recent Comments